Tandem Diabetes Stock Gets a Boost: Analyst Upgrade Signals 50%+ Upside Potential

Piper Sandler upgrades Tandem Diabetes to Overweight from Neutral, raises PT to $33 from $21. Mobi pump, pharmacy pricing, and international growth drive revenue upside.